Half-year report · Q2
6523.TEDINET S100UR3H
Period2024-04-01 → 2024-09-30
Filed2024-11-13
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥173.9bn | 2024-04-01 → 2024-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥353.9bn | 2023-04-01 → 2024-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥166.8bn | 2023-04-01 → 2023-09-30 | Cons. | Revenue IFRS |
| Operating income | ¥9.2bn | 2024-04-01 → 2024-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥4.2bn | 2023-04-01 → 2023-09-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥7.4bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | −¥13.2bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | −¥3.0bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥4.1bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | −¥12.9bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | −¥2.5bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥4.0bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss IFRS |
| Net income | −¥2.4bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss IFRS |
| Total assets | ¥525.4bn | at 2024-09-30 | Cons. | Assets IFRS |
| Total assets | ¥564.3bn | at 2024-03-31 | Cons. | Assets IFRS |
| Total assets | ¥570.4bn | at 2023-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥398.0bn | at 2024-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥425.2bn | at 2024-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥127.4bn | at 2024-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥139.2bn | at 2024-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥147.0bn | at 2023-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥138.8bn | at 2023-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥127.8bn | at 2024-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥139.5bn | at 2024-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥147.4bn | at 2023-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥33.0bn | at 2024-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥47.0bn | at 2024-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥61.4bn | at 2023-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥60.9bn | at 2023-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥13.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥41.3bn | 2023-04-01 → 2024-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥22.7bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥5.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥21.1bn | 2023-04-01 → 2024-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥2.1bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥20.9bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥39.1bn | 2023-04-01 → 2024-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥23.6bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥32.52 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥-102.48 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥-19.55 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥32.42 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥-102.48 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥-19.55 | 2023-04-01 → 2023-09-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 24.3% | at 2024-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 24.7% | at 2024-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 25.8% | at 2023-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | ¥1.6bn |
| Reconciling Itemsreconciling | revenue external | 2024-04-01 → 2024-09-30 | ¥1.6bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥4.3bn |
| jpcrp040300-q2r_E36976-000Diabetes Managementreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥48.3bn |
| jpcrp040300-q2r_E36976-000Diabetes Managementreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥48.3bn |
| jpcrp040300-q2r_E36976-000Diabetes Managementreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥6.4bn |
| jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥62.6bn |
| jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥62.6bn |
| jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥3.5bn |
| jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥61.5bn |
| jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥61.5bn |
| jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥3.6bn |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥172.3bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥172.3bn |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥13.5bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | ¥1.1bn |
| Reconciling Itemsreconciling | revenue external | 2023-04-01 → 2023-09-30 | ¥1.1bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥4.8bn |
| jpcrp040300-q2r_E36976-000Diabetes Managementreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥48.8bn |
| jpcrp040300-q2r_E36976-000Diabetes Managementreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥48.8bn |
| jpcrp040300-q2r_E36976-000Diabetes Managementreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥5.5bn |
| jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥61.0bn |
| jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥61.0bn |
| jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥2.5bn |
| jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥55.9bn |
| jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥55.9bn |
| jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥951m |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥165.7bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥165.7bn |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥8.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 812
| Item | Context | Value | Unit |
|---|---|---|---|
| Impairment losses pl IFRS | CurrentYTDDuration_jpcrp040300-q2r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember | － | JPY |
| Impairment losses pl IFRS | CurrentYTDDuration_ReportableSegmentsMember | 56000000 | JPY |
| Impairment losses pl IFRS | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Impairment losses pl IFRS | CurrentYTDDuration | 56000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2024-11-13 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第12期中（自 2024年４月１日 至 2024年９月30日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)ＰＨＣホールディングス株式会社 | |
| Company name in english cover page | FilingDateInstant | PHC Holdings Corporation | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長CEO 出口 恭子 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都千代田区有楽町一丁目13番２号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | 03-6695-9938 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)常務執行役員 最高財務責任者（CFO） 山口 快樹 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都千代田区有楽町一丁目13番２号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | 03-6695-9938 | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)常務執行役員 最高財務責任者（CFO） 山口 快樹 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E36976 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 65230 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)ＰＨＣホールディングス株式会社 | |
| Filer name in english | FilingDateInstant | PHC Holdings Corporation | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | IFRS | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2024-04-01 | |
| Current period end date | FilingDateInstant | 2024-09-30 | |
| Type of current period | FilingDateInstant | Q2 | |
| Current fiscal year end date | FilingDateInstant | 2025-03-31 | |
| Previous fiscal year start date | FilingDateInstant | 2023-04-01 | |
| Comparative period end date | FilingDateInstant | 2023-09-30 | |
| Previous fiscal year end date | FilingDateInstant | 2024-03-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts for operation (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |